Asahi Kasei Bioprocess to Unveil THESYS™ ACS ERGO Synthesis Column at TIDES USA
May 02 2024 - 2:00PM
Business Wire
Offering reduced changeover time while
maintaining safety and product quality
Generating cutting-edge therapeutics requires precision, safety,
and efficiency from manufacturing equipment. The next generation of
oligo manufacturing, the process of producing short sequences of
nucleotides (building blocks of DNA or RNA), innovation from Asahi
Kasei Bioprocess (AKB), the THESYS™ ACS ERGO synthesis column, will
be on display and demonstrated at Booth 213 at TIDES USA 2024 from
May 14th to 17th at the Hynes Convention Center in Boston. This new
synthesis column offers drastically reduced changeover time between
batches while maintaining user safety and product quality.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240502639431/en/
Concept image of the THESYS™ ACS ERGO
synthesis column. (Photo: Business Wire)
Following the success of AKB’s DAC ERGO™, a liquid
chromatography column, the company has continued advancing column
technology with the THESYS™ ACS ERGO. The THESYS ACS ERGO is
designed for oligonucleotide synthesis and includes an
operator-friendly design to facilitate a smooth and safe changeover
between runs. It provides the same reliable high-performance as
AKB’s other synthesis columns but is uniquely engineered to reduce
inefficiencies between batches – with upwards of an hour of time
savings as well as projected labor reduction.
The time-saving features of the THESYS™ ACS ERGO are achieved by
eliminating the use of threaded bolts in the changeover and
maintenance process, which can be tedious and time-consuming to
remove between runs. AKB has ergonomically designed the THESYS™ ACS
ERGO for faster changeover without cost to safety, which improves
customer efficiency while maintaining operator safety and product
reliability.
“Our new, bolt-free design is unique to the column market and
makes unpacking and cleaning far less time-consuming,” said Chris
Rombach, EVP at Asahi Kasei Bioprocess America (AKBA). “Every
feature of the ACS ERGO has been considered, with greater
productivity for manufacturers and operator safety as the top
priorities.”
THESYS™ ACS includes an innovative I-bar format that makes
removing the top of the column more efficient and a unique frame
with an integrated gearbox and wheel to facilitate smooth, safe
unpacking and cleaning. Furthermore, the column has a minimized
footprint to seamlessly integrate into the manufacturing floor.
In addition to its booth at the event, AKB will host a
‘Spotlight Presentation’ on May 16 at 12:20 p.m. in room 302 about
the oligo manufacturing process. Dr. Tom Krebstakies, Sales Manager
for Europe and Asia at AKB, will speak about innovations from
synthesis through concentration and the applicable equipment
considerations for effective technical implementation.
Attendees are invited to visit AKB at Booth 213 to explore new
products, witness live demos, and learn more about how AKB’s
innovations make manufacturing therapeutics easier.
Learn more about how AKB helps oligo process engineers quickly
improve throughput, efficiency, and costs.
About Asahi Kasei Bioprocess The Fluid Management
Business Unit of Asahi Kasei Bioprocess is devoted to solving
therapeutic product safety, efficiency, and purity challenges
within the pharmaceutical and bioprocessing industries. With
technology platforms for oligonucleotide synthesis, buffer
formulation, chromatography, and filtration, our bioprocess
systems, columns, and automation solutions advance GMP
manufacturing of critical drug substances around the world. Built
with pride, built with quality, built to exceed expectations.
“Built for You.” For more information, please visit
https://fluidmgmt.ak-bio.com.
About Asahi Kasei The Asahi Kasei Group contributes to
life and living for people around the world. Since its foundation
in 1922 with ammonia and cellulose fiber business, Asahi Kasei has
consistently grown through the proactive transformation of its
business portfolio to meet the evolving needs of every age. With
more than 48,000 employees worldwide, the company contributes to
sustainable society by providing solutions to the world’s
challenges through its three business sectors of Material, Homes,
and Health Care. For more information, visit
www.asahi-kasei.com.
Asahi Kasei is also dedicated to sustainability initiatives and
is contributing to reaching a carbon neutral society by 2050. To
learn more, visit https://www.asahi-kasei.com/sustainability/.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240502639431/en/
North America Contact: Asahi Kasei America Inc. Christian
OKeefe christian.okeefe@ak-america.com
Europe Contact: Asahi Kasei Europe GmbH Sebastian Schmidt
sebastian.schmidt@asahi-kasei.eu
Asahi Kasei Bioprocess Contact: Asahi Kasei Bioprocess
America, Inc. Steve Foy Steve.Foy@ak-bio.com